PRISMAP’s new web access platform, www.prismap.eu is used to display public information, alongside a private consortium section for data sharing and communication. This platform covers to date 24 different radionuclides in our portfolio, that can be used as ingredients in diagnostics, treatment, or for theranostics. Our platform allows scientists interested in biomedical research to easily access important information, such as the type of diagnostic, imaging, or treatment modality, that directly depends on the chemical, physical and nuclear properties of a given radionuclide, notably its different modes of radioactive decay, and often their combination.
For each radionuclide we provide general data, together with the mode of production and general applications of the radionuclides in biomedical research with links to published articles when available. We also give full specifications of the quality grades supplied by PRISMAP allowing to clarify if the radionuclide with its properties, and the range of purity grades accessible is appropriate for a given field of biomedical research.
New terminologies and standards have been introduced to account for the novel methods of production made available across the PRISMAP consortium, notably combining isotope mass separation and more established accelerator (cyclotron) and reactor methods. Sometimes the data is insufficiently known or not available at all. We have therefore started to produce new data, that can be useful in the assessment of the physical and nuclear parameters, purity grades, or their application in biomedical research. Examples of application in targeted molecular therapies are particularly relevant, as some of our radionuclides can be supplied in high molar activities, which make the synthesis and use in radiopharmaceuticals targeting specific tumour receptors possible.
PRISMAP can provide access, free of charge, to new radionuclides and new grades of these to researchers across Europe and beyond, either directly in their laboratory, or by accessing one of our biomedical research centres licensed to handle these new radionuclides.
In a first call for proposals, 9 highly innovative user projects proposed by research teams active across Europe (BE, DE, ES, FR, IT) were selected by an expert panel. For a second call the evaluation is ongoing. The selected projects cover a wide range of disciplines in radiochemistry, radiation physics, radiopharmacy, preclinical and translational biomedical research, and target different types of cancer and experimental approaches. The results will be public once available, and reported at conferences, in scientific articles, and at PRISMAP’s public events as already done, e. g. introducing new theranostics application for a mass separated Sm-153-DOTATATE radiobioconjugate or implementing a clinical translation of Tb-161-DOTATATE, allowing a possible comparison with the Lu-177-DOTATATE (Luthatera®) in the years to come.
Targeted alpha therapy, an efficient mode of treatment exploiting alpha emitters, also benefits from research and data produced in PRISMAP. This is particularly true for radionuclides which present short half-lives and require efficient dispatch and special licenses to handle. To this end, synthetic guidelines were edited to raise awareness of the regulatory framework for transport and use of radionuclides in biomedicine, be it in early preclinical research or for clinical translation.
